UCSF HELEN DILLER FAMILY COMPREHENSIVE CANCER CENTER

Recommendations

Info

Presentations Association of mammographic density measures and breast cancer ‘intrinsic’ molecular subtypes Authors*: Aaron D. Norman, Rulla M. Tamimi, Christopher G. Scoe, Kimberly A. Bertrand, Matthew R. Jensen, Daniel W. Visscher, Fergus J. Couch, John Shepherd, Bo Fan, Yunn-Yi Chen, Lin Ma, Andrew Beck, Vernon S. Pankratz, Karla Kerlikowske, Celine M. Vachon Pres #: 2593 Section: 36 Presentation Date/Time: Monday, April 18: 1:00-5:00PM Location: Presentation Type: Poster Session Kerlikowski Lab Expertise: My lab focuses on breast imaging and the epidemiology of invasive breast cancer, DCIS and breast density, and risk prediction models for invasive breast cancer. We have developed cohorts of women at risk for invasive breast cancer and DCIS and developed comprehensive databases that include breast imaging, pathologic, clinical, biomarker, and risk factor data, as well as follow-up for subsequent disease and death. http://cancer.ucsf.edu/people/profiles/kerlikowske_karla.3457 __________________________________________________________________________ Common genetic variants associated with breast cancer risk used in the Athena study to enhance models identifying women for breast cancer chemoprevention Authors*: Sarah Theiner, Sarah D. Sawyer, Paige Kendall, Alexandra S. Perry, Denise Wolf, Scott Huntsman, Bo Pan, Jeffery A. Tice, David A. Pearce, Thomas Cink, Laura Esserman, Elad Ziv, Laura van ‘t Veer Pres #: 2623 Section: 37 Presentation Date/Time: Monday, April 18: 1:00-5:00PM Location: Presentation Type: Poster Session van ‘t Veer Lab Expertise: Dr. van ’t Veer’s research focuses on personalized medicine & advancing patient management based on knowledge of the genetic makeup of the tumor as well as the genetic makeup of the patient. Her laboratory investigates human kinases & how kinase inhibitors elicit response & resistance, which is also utilized to understand agent efficacy in the I-SPY 2 TRIAL. She is the PI of the Athena Breast Health Network, a 150,000 women cohort study evaluating new paradigms to enhance breast health. She leads the targeted genome testing of 100,000 women for 9 breast cancer susceptibility genes and a selection of ~100 known susceptibility SNPs. She is one of the PIs for the NIH Big Data to Knowledge Center Translational Genomics, facilitating worldwide standardization of sharing annotated genomics data. http://cancer.ucsf.edu/people/profiles/vantveer_laura.3358 *<strong>UCSF</strong> authors in bold 26
Presentations A stem cell program in metastatic human breast cancer Authors*: Zena Werb Pres #: Section: Presentation Date/Time: Monday, April 18: 1:10-1:35PM Location: New Orleans Theater C Presentation Type: Major Symposium __________________________________________________________________________ Molecular evolution and taxonomy of melanoma Authors*: Boris C. Bastien Pres #: Section: Presentation Date/Time: Monday, April 18: 1:30-1:55PM Location: Room 391 Presentation Type: Recent Advances in Organ Site Research Bastian Lab Expertise: My laboratory is interested in the genetic alterations involved in skin cancer pathogenesis and predisposition as well as in understanding their role in biology, markers to improve diagnosis, and targets for treatment. __________________________________________________________________________ Molecular mechanisms of driver mutations in glioma Authors*: Joseph F. Costello Pres #: Section: Presentation Date/Time: Monday, April 18: 2:00-2:25PM Location: Room 354 Presentation Type: Recent Advances in Organ Site Research Costello Lab Expertise (Limit 800 characters): Our goal is to understand the full life history of human tumors, from the first mutation and epimutation through clonal selection and tumor recurrence. We use NGS to discover patterns and interdependencies of genetic mutations, epigenetic alterations and gene expression changes. Current projects incorporate MRI guided tumor biopsies and treatment data with longitudinal genomics to allow the reconstruction of tumor evolution in the context of the human tumor in vivo. We recently discovered the mechanism by which mutations in the TERT gene promoter leads to telomerase activation. https://costellolab.ucsf.edu/ *<strong>UCSF</strong> authors in bold 27
Page 1 and 2: UCSF HELEN DILLER FAMILY COMPREHENS
Page 3 and 4: HDFCCC Overview A Designated NCI Co
Page 5 and 6: HDFCCC Overview Core Capabilities S
Page 7 and 8: Presentations Presentations View fu
Page 9 and 10: Presentations Whole exome and targe
Page 11 and 12: Presentations SRC mediates intrinsi
Page 13 and 14: Presentations Deregulated Myc is an
Page 15 and 16: Presentations BRM loss promotes tum
Page 17 and 18: Presentations HER3 is a functional
Page 19 and 20: Presentations MicroRNA-466 regulate
Page 21 and 22: Presentations Systematic search for
Page 23 and 24: Presentations Toxicity, bioavailabi
Page 25: Presentations The genetic evolution
Page 29 and 30: Presentations Inhibition of fatty-a
Page 31 and 32: Presentations Genetic prediction of
Page 33 and 34: Presentations Overcoming resistance
Page 35 and 36: Presentations Direct analysis of tu
Page 37: Presentations Caffeic acid phenethy

UCSF HELEN DILLER FAMILY COMPREHENSIVE CANCER CENTER

Create successful ePaper yourself

Delete template?

Save as template?